A Phase 1b/2 Study of PEP503 (Radioenhancer) With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer

Trial Profile

A Phase 1b/2 Study of PEP503 (Radioenhancer) With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs NBTXR 3 (Primary) ; Cisplatin
  • Indications Head and neck cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors PharmaEngine
  • Most Recent Events

    • 28 Nov 2016 According to Nanobiotix media release, complete data will be available by second half of 2017.
    • 19 Oct 2016 According to PharmaEngine media release, company announced today that the first patient has been dosed in this study.
    • 19 Oct 2016 According to PharmaEngine media release, status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top